Alaunos Therapeutics, Inc. (NASDAQ:TCRT) to Post FY2023 Earnings of ($0.17) Per Share, Cantor Fitzgerald Forecasts

Alaunos Therapeutics, Inc. (NASDAQ:TCRTGet Rating) – Analysts at Cantor Fitzgerald dropped their FY2023 earnings estimates for Alaunos Therapeutics in a report released on Wednesday, March 8th. Cantor Fitzgerald analyst P. Agrawal now anticipates that the company will earn ($0.17) per share for the year, down from their prior forecast of ($0.16). The consensus estimate for Alaunos Therapeutics’ current full-year earnings is ($0.16) per share.

Alaunos Therapeutics Price Performance

NASDAQ:TCRT opened at $0.51 on Monday. The firm has a market capitalization of $122.82 million, a P/E ratio of -2.84 and a beta of 0.16. Alaunos Therapeutics has a 1-year low of $0.41 and a 1-year high of $4.01. The company’s fifty day moving average price is $0.67 and its 200-day moving average price is $1.17.

Institutional Trading of Alaunos Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in TCRT. Discovery Capital Management LLC CT acquired a new position in shares of Alaunos Therapeutics in the second quarter worth about $17,515,000. Laurion Capital Management LP purchased a new position in Alaunos Therapeutics during the second quarter valued at $5,319,000. JPMorgan Chase & Co. purchased a new position in Alaunos Therapeutics during the second quarter valued at $5,231,000. State Street Corp lifted its holdings in Alaunos Therapeutics by 268.3% during the third quarter. State Street Corp now owns 3,178,423 shares of the company’s stock valued at $5,467,000 after purchasing an additional 2,315,397 shares in the last quarter. Finally, Millennium Management LLC purchased a new position in Alaunos Therapeutics during the second quarter valued at $2,690,000. Institutional investors and hedge funds own 34.36% of the company’s stock.

Alaunos Therapeutics Company Profile

(Get Rating)

Alaunos Therapeutics, Inc is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs.

Featured Articles

Earnings History and Estimates for Alaunos Therapeutics (NASDAQ:TCRT)

Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.